0 false false false false false false false false false false true false false false false false false No description of principal activity 2023-04-01 Sage Accounts Production Advanced 2023 - FRS102_2023 149,621 135,621 14,000 14,000 27,030 27,030 27,030 xbrli:pure xbrli:shares iso4217:GBP 2700296 2023-04-01 2024-03-31 2700296 2024-03-31 2700296 2023-03-31 2700296 2022-04-01 2023-03-31 2700296 2023-03-31 2700296 2022-03-31 2700296 core:PlantMachinery 2023-04-01 2024-03-31 2700296 bus:Director4 2023-04-01 2024-03-31 2700296 bus:Director9 2023-04-01 2024-03-31 2700296 core:PlantMachinery 2024-03-31 2700296 core:WithinOneYear 2023-03-31 2700296 core:ShareCapital 2024-03-31 2700296 core:ShareCapital 2023-03-31 2700296 core:SharePremium 2024-03-31 2700296 core:SharePremium 2023-03-31 2700296 core:CapitalRedemptionReserve 2024-03-31 2700296 core:CapitalRedemptionReserve 2023-03-31 2700296 core:RetainedEarningsAccumulatedLosses 2024-03-31 2700296 core:RetainedEarningsAccumulatedLosses 2023-03-31 2700296 core:CostValuation core:Non-currentFinancialInstruments 2024-03-31 2700296 core:Non-currentFinancialInstruments 2024-03-31 2700296 core:Non-currentFinancialInstruments 2023-03-31 2700296 core:PlantMachinery 2023-03-31 2700296 bus:SmallEntities 2023-04-01 2024-03-31 2700296 bus:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 2700296 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 2700296 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 2700296 bus:FullAccounts 2023-04-01 2024-03-31
COMPANY REGISTRATION NUMBER: 2700296
NICHE STRATEGIC HEALTH PARTNERS LTD
Filleted Unaudited Financial Statements
For
31 March 2024
NICHE STRATEGIC HEALTH PARTNERS LTD
Statement of Financial Position
31 March 2024
2024
2023
Note
£
£
£
Fixed assets
Tangible assets
4
14,000
14,000
Investments
5
27,030
27,030
--------
--------
41,030
41,030
Current assets
Debtors
6
36,863
81,425
Cash at bank and in hand
1,347
6,794
--------
--------
38,210
88,219
Creditors: amounts falling due within one year
7
9
--------
--------
Net current assets
38,210
88,210
--------
---------
Total assets less current liabilities
79,240
129,240
Provisions
Taxation including deferred tax
2,117
2,117
--------
---------
Net assets
77,123
127,123
--------
---------
Capital and reserves
Called up share capital
54,060
54,060
Share premium account
46,492
46,492
Capital redemption reserve
11,623
11,623
Profit and loss account
( 35,052)
14,948
--------
---------
Shareholders funds
77,123
127,123
--------
---------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
NICHE STRATEGIC HEALTH PARTNERS LTD
Statement of Financial Position (continued)
31 March 2024
These financial statements were approved by the board of directors and authorised for issue on 27 September 2024 , and are signed on behalf of the board by:
MR J Fitton
Ms K H Jury
Director
Director
Company registration number: 2700296
NICHE STRATEGIC HEALTH PARTNERS LTD
Notes to the Financial Statements
Year ended 31 March 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 4th Floor, Trafford House, Chester Road, Stretford, Manchester, M32 0RS.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Consolidation
The company has taken advantage of the option not to prepare consolidated financial statements contained in Section 398 of the Companies Act 2006 on the basis that the company and its subsidiary undertakings comprise a small group.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Plant and machinery
-
15% reducing balance
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Provisions
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event, it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense. Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised as a finance cost in profit or loss in the period it arises.
4. Tangible assets
Plant and machinery
Total
£
£
Cost
At 1 April 2023 and 31 March 2024
149,621
149,621
---------
---------
Depreciation
At 1 April 2023 and 31 March 2024
135,621
135,621
---------
---------
Carrying amount
At 31 March 2024
14,000
14,000
---------
---------
At 31 March 2023
14,000
14,000
---------
---------
5. Investments
Shares in group undertakings
£
Cost
At 1 April 2023 and 31 March 2024
27,030
--------
Impairment
At 1 April 2023 and 31 March 2024
--------
Carrying amount
At 31 March 2024
27,030
--------
At 31 March 2023
27,030
--------
6. Debtors
2024
2023
£
£
Amounts owed by group undertakings and undertakings in which the company has a participating interest
29,303
73,865
Other debtors
7,560
7,560
--------
--------
36,863
81,425
--------
--------
7. Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans and overdrafts
9
----
----
8. Related party transactions